Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989865 | 0.94 | SYK (0.41) | SYKACVR1BTGFBR1ACVRL1PIK3R2 | |
| SCHEMBL19989873 | 0.90 | SYK (0.38) | SYKPIK3R2 | |
| SCHEMBL19989922 | 0.90 | SYK (0.38) | SYK | |
| SCHEMBL19989874 | 0.84 | SYK (0.38) | SYKTGFBR1CCNT1CDK9 | |
| SCHEMBL19989784 | 0.84 | PIK3R2 (0.41) | HCRTR1HCRTR2TGFBR1PIK3R2 | |
| SCHEMBL19989975 | 0.84 | SYK (0.41) | SYKPIK3R2 | |
| SCHEMBL19989842 | 0.81 | PIK3R2 (0.37) | HCRTR1HCRTR2TGFBR1PIK3R2 | |
| SCHEMBL19989744 | 0.81 | SYK (0.43) | SYKCCNT1CDK9 | |
| SCHEMBL19989934 | 0.79 | PIK3R2 (0.35) | HCRTR1HCRTR2TGFBR1PIK3R2 | |
| SCHEMBL19990083 | 0.78 | PIK3R2 (0.44) | TGFBR1PIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT1 | SYK 531/4885HCRTR1 4002/4885HCRTR2 3803/4885 |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, AKT1 | SYK 531/4885HCRTR1 4002/4885HCRTR2 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.